Recent 8-K filings for MLTX
Highest-materiality recent filing
MoonLake aligns with FDA on BLA for sonelokimab in HS; Q1 cash $357.9M
- FDA pre-BLA meeting positive; alignment on submission plans, adolescent data inclusion, and safety strategy.
- BLA submission planned for end of Sep 2026; Priority Review decision expected within 60 days.
-
Master Commercial Supply Agreement signed May 22, 2026 with Vetter for manufacturing pre-filled application systems.
-
MoonLake aligns with FDA on BLA for sonelokimab in HS; Q1 cash $357.9M
FDA pre-BLA meeting positive; alignment on submission plans, adolescent data inclusion, and safety strategy.
-
Phase 2 S-OLARIS trial: 81% of SLK-treated patients achieved ASAS40 response at Week 12 (n=26, mNRI).
-
MoonLake gets FDA clarity on SLK in HS; no new trials needed for BLA submission
FDA confirms MoonLake can establish substantial evidence of effectiveness using existing VELA-1, VELA-2, and MIRA trials; no additional HS trials required.
-
MoonLake Immunotherapeutics raises $75M in equity offering of 7.1M shares at $10.50/share
Offering of 7,142,857 Class A ordinary shares at $10.50 per share for gross proceeds of $75M.
-
MoonLake Q3 2025: $380.5M cash, positive Phase 2 PPP data for Sonelokimab
Cash and equivalents $380.5M as of Sept 30, 2025; runway into H2 2027.
-
VELA-1 achieved HiSCR75 at week 16 with 34.8% vs 17.5% placebo, delta 17.3% (p<0.001).
-
MoonLake Q2 cash $425M; Phase 3 HS readout expected Sept 2025
R&D expenses Q2 $49.8M (up from $36.5M Q1) on trial ramp-up and BLA preparation.
-
MoonLake shareholders elect all director nominees and approve auditor and say-on-pay at AGM
All three Class III director nominees elected: Dr. Jorge Santos da Silva, Simon Sturge, Dr. Andrew Phillips with over 53M votes for each.
-
Cash, cash equivalents and short-term marketable debt securities of $480.1M as of March 31, 2025.
-
MoonLake to post investor presentation for Capital Markets Day; no specific figures disclosed
MoonLake Immunotherapeutics will post an investor presentation for its Capital Markets Day on April 29, 2025.
-
MoonLake secures up to $500M non-dilutive loan from Hercules Capital; $75M drawn at close
Up to $500M non-dilutive term loan facility from Hercules Capital; $75M funded at close on March 31, 2025.
-
MoonLake reports FY 2024 net loss of $121.2M, cash of $448M; advances sonelokimab to Phase 3
Net loss for 2024 was $121.2M, compared to $44.1M in 2023, driven by increased R&D spending.
-
MoonLake director resigns; CEO, CSO, CFO each to receive $4M equity grants in Jan 2025
Dr. Kara Lassen resigns from Board effective Dec 31, 2024, due to new role at Roche Pharma; no dispute with Company.
-
MoonLake Q3 cash $493.9M; Phase 3 HS readout on track for mid-2025
Cash, equivalents and short-term debt securities of $493.9M as of Sep 30; runway to end of 2026.
-
Investor presentation covers financial position, near-term catalysts, and publication roadmap.
-
Q2 2024 cash, equivalents and short-term debt securities of $519.8M; cash runway to end-2026 unchanged.
-
FDA and EMA back MoonLake's Phase 3 program for sonelokimab in psoriatic arthritis
FDA and EMA unanimously supported MoonLake's proposed Phase 3 IZAR program for sonelokimab in PsA.
-
Director nominees Catherine Moukheibir (50.4M for) and Dr. Ramnik Xavier (53.9M for) elected; 4.24M broker non-votes.
-
MoonLake Q1 cash $547.1M; positive FDA/EMA feedback for Phase 3 sonelokimab in HS
Cash and equivalents $547.1M at March 31, 2024, expected to fund operations to end of 2026.
-
MoonLake reports 24-week PsA data with ~60% ACR50; plans Phase 3 HS trials in Q2 2024
ARGO trial: ~60% ACR50 at week 24; ~40% ACR70; >80% PASI90; ~60% PASI100; low discontinuation ~5%.
-
MoonLake FY 2023 net loss $44.1M; cash $511M; sonelokimab Phase 3 prep advances
Cash, cash equivalents and short-term marketable debt securities $511.0M at Dec 31, 2023, up from $496M at Sep 30, 2023.
-
MoonLake gets FDA & EMA support for Phase 3 sonelokimab in hidradenitis suppurativa
FDA and EMA both support Phase 3 design for sonelokimab (SLK) in HS; trial named VELA.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.75 · Most common event other_material